Dynamic stretching programme for children with cerebral palsy

Submission date 05/07/2023	Recruitment status Recruiting	[X] Prospectively registered[X] Protocol		
Registration date	Overall study status Ongoing	Statistical analysis plan		
01/08/2023		Results		
Last Edited	Condition category Nervous System Diseases	Individual participant data		
07/03/2025		[X] Record updated in last year		

Plain English summary of protocol

Background and study aims

Cerebral palsy (CP) is caused when babies suffer brain injury from a lack of oxygen in the brain. Children with CP often develop stiff muscles. They often have difficulty walking and moving and that makes it difficult for them to join in many different activities. Exercises prescribed by Physiotherapists become a big part of their lives and aim to train their muscles, stop them from becoming stiff and help children participate in activities. Exercises to stretch tight muscles to maintain or improve movement are often used by physiotherapists in children with CP. However, there is wide variability in the stretching exercise programmes used. Therefore, professional groups have highlighted the need for evidence-based physiotherapy exercise programmes in children with CP. The aim of this study is to assess the effectiveness of a stretching programme compared to usual care in children with CP.

Who can participate?

Children aged 4 to 11 years with spastic cerebral palsy

What does the study involve?

Participants will be randomly allocated to either the intervention (exercise programme) group or the usual NHS physiotherapy group. The intervention arm will involve six sessions with the physiotherapist over 16 weeks. Children will receive an exercise programme, which includes specific dynamic muscle stretching exercises. The usual care group will receive the usual NHS physiotherapy treatment, involving one session to receive advice and guidance on their usual exercise and activity programme but does not include specific muscle dynamic stretches. Children or their parents/guardians in both groups will be required to fill out a questionnaire when entering the study and again at 6 and 12 months. Participants will also receive a clinical assessment upon entering the study and again at 6 months.

What are the possible benefits and risks of participating?

As with any form of exercise, children may experience delayed muscle soreness on movement and/or mild altered walking (limping) for a few days after completing some of the exercises suggested by the physiotherapist. The benefit of participating is that the information from this study will be used to help treat other children with CP more effectively.

Where is the study run from?

The study will be centrally managed by the Surgical Intervention Trials Unit (SITU), in collaboration with the Oxford Clinical Trials Unit (OCTRU) (UK)

When is the study starting and how long is it expected to run for? January 2023 to September 2026

Who is funding the study?

National Institute for Health and Care Research (NIHR), Health Technology Assessment (HTA) Programme (UK)

Who is the main contact?

- 1. Tim Theologis, tim.theologis@msd.ox.ac.uk
- 2. Megan Stone, megan.stone@ndorms.ox.ac.uk

Contact information

Type(s)

Scientific

Contact name

Ms Megan Stone

Contact details

Surgical Intervention Trials Unit The Botnar Research Centre Windmill Road Oxford United Kingdom OX3 7LD +44 (0)1865 737210 Megan.stone@ndorms.ox.ac.uk

Type(s)

Principal investigator

Contact name

Prof Tim Theologis

ORCID ID

https://orcid.org/0000-0002-4758-9081

Contact details

University of Oxford
Botnar Institute for Musculoskeletal Sciences
Windmill Road
Oxford
United Kingdom
OX3 7LD
+44 (0)7770901483
tim.theologis@msd.ox.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

326645

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

CPMS 57141, IRAS 326645

Study information

Scientific Title

Clinical effectiveness of a child-specific dynamic stretching programme, compared to usual care, for ambulant children with spastic cerebral palsy (SPELL trial): a parallel group randomised controlled trial

Acronym

SPELL

Study objectives

A child-specific dynamic stretching programme has superior clinical effectiveness compared to usual care for ambulant children with spastic cerebral palsy.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 11/07/2023, East of England - Essex Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8106; essex.rec@hra.nhs.uk), ref: 23 /EE/0153

Study design

Randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Cerebral palsy

Interventions

SPELL is a randomised controlled trial with 1:1 allocation. Follow-up assessors will be blinded to the randomisation allocation.

Participants will be identified through the Cerebral Palsy Integrated Pathway (CPIP) Network and recruited from NHS Trusts, providing care for children and young people with CP, where they will be assessed for eligibility by the clinical team, both supported by the local PI and research team in case of uncertainty.

Children and their parent(s) will be approached as part of their annual community physiotherapy CPIP review or other routine CP clinical care attendance and/or will be sent letters with study information. They will have the opportunity at their appointment to ask any questions they have about the study.

Screening forms will be completed at each site. These will include demographic questions for eligible patients and detail any reasons given for exclusion and non-participation.

Participants will be asked to sign an assent form whilst the parent/carer will be asked to sign a consent form on behalf of their child.

Randomisation will take place once informed consent has been given, eligibility has been confirmed and baseline assessments have been made. During the baseline assessment participants, with the support of their parent/carer will be asked to complete a baseline assessment questionnaire, which will include baseline measurements for the primary and secondary outcomes.

Clinician-assessed outcomes (ie passive range of lower limb joint motion and motor function) at baseline will be recorded electronically by a physiotherapist at site and before learning the outcome of the randomisation. All data will be entered into the study database (REDCap).

Those randomly allocated to the dynamic stretching exercise programme will receive six physiotherapy sessions over 16 weeks and will be requested to complete follow-up questionnaires via a link in an email or by paper through the post at 6 and 12 months. Clinician-assessed outcomes will be assessed at a face-to-face clinic appointment at 6 months by a blinded physiotherapist/assistant practitioner who is blind to the treatment allocation and has not been involved in the delivery of the intervention or usual care.

Those randomly allocated to the usual NHS care will receive one session of usual care advice, with a physiotherapist/assistant practitioner. Participants allocated to this group will also be sent a link via email or a paper copy of the questionnaire to complete at 6 months and 12 months. They will also receive a blinded clinician assessment at the 6-month timepoint.

Intervention Type

Behavioural

Primary outcome(s)

Functional mobility measured using the patient/parent-reported Gait Outcomes Assessment List (GOAL) questionnaire at 6 months

Key secondary outcome(s))

- 1. Passive joint range of motion measured using the CPIP protocol of lower limb joint range of motion at 6 months
- 2. Motor function measured using the Timed Up and Go (TUG) test at 6 months

- 3. Functional mobility measured using the patient/parent-reported Gait Outcomes Assessment List (GOAL) questionnaire at 12 months
- 4. Independence measured using GOAL subdomain A at 6 and 12 months
- 5. Balance measured using GOAL subdomains A, B, D at 6 and 12 months
- 6. Pain and discomfort measured using GOAL subdomain C at 6 and 12 months
- 7. Health-related quality of life measured using EQ-5D-Y at 6 and 12 months
- 8. Educational outcomes measured using educational attendance records (days) at 6 and 12 months
- 9. Patient/parent exercise adherence self-reported at 6 and 12 months
- 10. Additional physiotherapy treatment self-reported at 6 and 12 months

Completion date

01/09/2026

Eligibility

Key inclusion criteria

- 1. Children 4-11 years (i.e. from their 4th birthday to the day before their 12th birthday)
- 2. Diagnosis of spastic CP (bilateral or unilateral) GMFCS levels I–III
- 3. Willing for their community physiotherapy service and GP to be informed of their participation in the trial

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

4 years

Upper age limit

11 years

Sex

All

Key exclusion criteria

- 1. Patient has had orthopaedic surgery of the lower limbs or selective dorsal rhizotomy in the past 12 months or planned (i.e. date confirmed) in the next 6 months
- 2. Patient has had lower limb botulinum toxin injections or serial casting in the past 4 months or planned (i.e. date confirmed) in the next 6 months
- 3. Patient is regularly performing a structured dynamic exercise programme focused on dynamic stretching as part of their usual physiotherapy routine
- 4. Patient is unable to comply with the assessment procedures and exercise programme with or without support by their parent/guardian

Date of first enrolment

28/11/2023

Date of final enrolment

28/02/2026

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

University Hospitals Dorset NHS Foundation Trust

Management Offices Poole Hospital Longfleet Road Poole United Kingdom BH15 2JB

Study participating centre Derbyshire Healthcare NHS Foundation Trust

Trust Headquarters Kingsway Hospital Kingsway Derby United Kingdom DE22 3LZ

Study participating centre

Gloucestershire Health and Care NHS Foundation Trust

Edward Jenner Court 1010 Pioneer Avenue Gloucester Business Park Gloucester United Kingdom GL3 4AW

Study participating centre
Alder Hey Children's NHS Foundation Trust
Alder Hey Hospital

Eaton Road West Derby Liverpool United Kingdom L12 2AP

Study participating centre Solent NHS Trust

Solent NHS Trust Headquarters Highpoint Venue Bursledon Road Southampton United Kingdom SO19 8BR

Study participating centre Isle of Wight NHS - Hq

St Mary's Hospital Parkhurst Road Newport United Kingdom PO30 5TG

Study participating centre Barts Health NHS Trust

The Royal London Hospital 80 Newark Street London United Kingdom E1 2ES

Study participating centre Coventry and Warwickshire Partnership NHS Trust

Wayside House Wilsons Lane Coventry United Kingdom CV6 6NY

Study participating centre

St George's University Hospitals NHS Foundation Trust

St George's Hospital Blackshaw Road Tooting London United Kingdom SW17 0QT

Study participating centre Leeds Community Healthcare NHS Trust

3 White Rose Office Park Millshaw Park Lane Leeds United Kingdom LS11 0DL

Study participating centre West Suffolk NHS Foundation Trust

West Suffolk Hospital Hardwick Lane Bury St. Edmunds United Kingdom IP33 2QZ

Study participating centre The Royal Wolverhampton NHS Trust

New Cross Hospital Wolverhampton Road Heath Town Wolverhampton United Kingdom WV10 0QP

Study participating centre Northern Care Alliance NHS Foundation Trust

Salford Royal Stott Lane Salford United Kingdom M6 8HD

Study participating centre Torbay and South Devon NHS Foundation Trust

Torbay Hospital Newton Road Torquay United Kingdom TQ2 7AA

Study participating centre
Mid Cheshire Hospitals NHS Foundation Trust
Leighton Hospital
Leighton
Crewe
United Kingdom
CW1 4QJ

Sponsor information

Organisation

University of Oxford

ROR

https://ror.org/052gg0110

Funder(s)

Funder type

Government

Funder Name

NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR135131

Results and Publications

Individual participant data (IPD) sharing plan

Upon completion of the trial, and with appropriate participant consent, anonymised research data will be shared with other organisations on request to the Chief Investigator Tim Theologis and in accordance with the data sharing policies of OCTRU, the Sponsor and funder. Requests for data (anonymised trial participant level data) will be provided at the end of the trial to external researchers who provide a methodologically sound proposal to the trial team (and who

will be required to sign a data sharing access agreement with the Sponsor) and in accordance with the NIHR guidance. After the end of the trial an anonymised trial dataset will be created and stored, and may be shared with other researchers upon request. Participant consent for this is included in the informed consent form for the trial.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet			10/12/2024		Yes
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
<u>Protocol file</u>	version 1.0	06/06/2023	05/09/2023	No	No
<u>Protocol file</u>	version 2.0	27/09/2023	10/12/2024	No	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes